* Presentation of efficacy trends from ongoing phase I/II trial of oncolytic HSV * Poster selected by ESMO for presentation in press conference
MARTINSRIED, Germany, June 29, 2007.--The biotech company MediGene AG (Frankfurt, Prime Standard: MDG) announces that a case report from the ongoing clinical trial of MediGene's cancer killing virus will be presented in a press conference held by the European Society for Medical Oncology. Out of more than 300 posters accepted for the conference, only five were chosen for presentation in the press conference.
The event will take place on Friday, July 6, at 12:30 MEST at the ESMO conference in Lugano, Switzerland (ECLU). Dr. Axel Mescheder, Head of Clinical Research and Development at MediGene, will present the data in the press conference as well as in a poster presentation during the conference.
The phase I/II trial of NV1020 for the treatment of liver metastases of colorectal cancer is being conducted at seven leading cancer centers in the US. In September 2006, MediGene announced positive safety and efficacy data from an interim analysis of this study. The poster presented at the ESMO conference shows efficacy data in a case study for the first time.
Dr. Ulrich Delvos, Chief Operating Officer of MediGene, comments. "We are delighted and proud that the European Society for Medical Oncology has decided to present a case study from our trial in a press conference. Considering the number of studies presented on Europe's largest cancer congress, this emphasizes the innovation and the potential of this approach to fight cancer."
Journalists interested in joining the press conference please contact email@example.com
This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgmen t of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGeneTM is a trademarks of MediGene AG
- ends -
MediGene AG is a publicly quoted (Frankfurt: Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company with a drug on the market. A second drug has been approved by the FDA. A third drug was recently inlicensed to market this drug in Europe. In addition, several drug candidates are currently in clinical development. MediGene also possesses innovative platform technologies.
Contact MediGene AG: Email:
Fax: ++49 - 89 - 85 65 - 2920 Julia Hofmann/Dr. Georg Dönges, Public Relations Tel.: ++49 - 89 - 85 65 - 3317 Dr. Michael Nettersheim, Investor Relations Tel.: ++49 - 89 - 85 65 - 2946